An Australian study has discovered that a popular diabetes drug can reduce the risk of kidney failure and improve heart and lung health.
The study, conducted at the University of New South Wales and published in The Lancet Diabetes & Endocrinology, analyzed data from 11 clinical trials on diabetes and obesity drugs, involving over 85,000 participants, with more than 67,000 having type 2 diabetes.
Key Findings
The research revealed that these drugs can lead to a 16 percent reduced risk of kidney failure, a 13 percent reduced risk of major cardiovascular events, and a 12 percent lower risk of death.
These clinical trials focused on 7 drugs known as glucagon-like peptide-1 (GLP-1) receptor agonists, including the commonly known semaglutide, marketed as âOzempic.â
How Does It Work?
These drugs mimic the activity of the hormone GLP-1, released from the small intestines, to help lower blood sugar levels and promote a feeling of fullness while slowing down digestion.
Why This is Important
The study, led by Dr. Sunil Badve, is the first to demonstrate the protective effects of these drugs against kidney failure and end-stage kidney disease, highlighting their potential in the treatment of type 2 diabetes, obesity, cardiovascular disease, and chronic kidney disease.
Drug Could Help Patients With Chronic Kidney Disease
Approximately 2 million Australians suffer from chronic kidney disease, and the study suggests that GLP-1 receptor agonists could have a significant impact on addressing this healthcare challenge.
Senior author Vlado Perkovic emphasized the importance of incorporating these findings into clinical practice to improve access to these drugs for those who can benefit from them.
